Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 14.51% is 35% below its 3-year average of 22.39%, near the low end of its 3-year range (14.11%–28.39%).
As of the fiscal period ended Tuesday, June 30, 2026. 19.46% below its 12-month average of 18.01%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 14.51%.
RETURN ON EQUITY (ROE)
14.51%
RETURN ON EQUITY (ROE) AVG TTM
18.01%
RETURN ON EQUITY (ROE) AVG 3Y
22.02%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-19.46%
CURRENT VS 3Y AVG
-34.14%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
13.01%
median of 84 covered companies
CURRENT VS SECTOR MEDIAN
+11.50%
vs the sector median at left
GE HealthCare Technologies Inc.
Market Cap
$29.99B
Return on Equity (ROE)
14.51%
TTM Avg
18.01%
3Y Avg
22.02%
5Y Avg
N/A
Market Cap
$29.48B
Return on Equity (ROE)
83.10%
TTM Avg
66.19%
3Y Avg
56.82%
5Y Avg
52.60%
Market Cap
$30.65B
Return on Equity (ROE)
-22.60%
TTM Avg
-10.46%
3Y Avg
-1.37%
5Y Avg
1.10%
Market Cap
$30.72B
Return on Equity (ROE)
7062.40%
TTM Avg
-2178.82%
3Y Avg
-341.14%
5Y Avg
-117.12%
Market Cap
$29.03B
Return on Equity (ROE)
5.97%
TTM Avg
9.02%
3Y Avg
4.86%
5Y Avg
4.86%
Market Cap
$31.74B
Return on Equity (ROE)
23.13%
TTM Avg
23.30%
3Y Avg
22.33%
5Y Avg
21.49%
Market Cap
$32.75B
Return on Equity (ROE)
38.14%
TTM Avg
28.93%
3Y Avg
25.01%
5Y Avg
22.95%
Market Cap
$26.23B
Return on Equity (ROE)
18.89%
TTM Avg
16.95%
3Y Avg
19.08%
5Y Avg
20.56%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GE HealthCare Technologies Inc. (GEHC) | $29.99B | 14.51% | 18.01% | 22.02% | N/A |
| Zoetis Inc. (ZTS)vs › | $29.48B | 83.10% | 66.19% | 56.82% | 52.60% |
| Centene Corp. (CNC)vs › | $30.65B | -22.60% | -10.46% | -1.37% | 1.10% |
| Mettler-Toledo International Inc. (MTD)vs › | $30.72B | 7062.40% | -2178.82% | -341.14% | -117.12% |
| Medline Inc. (MDLN)vs › | $29.03B | 5.97% | 9.02% | 4.86% | 4.86% |
| Alcon Inc. (ALC)vs › | $31.45B | 2.96% | 4.58% | 3.90% | 2.45% |
| ResMed Inc. (RMD)vs › | $31.74B | 23.13% | 23.30% | 22.33% | 21.49% |
| DexCom, Inc. (DXCM)vs › | $32.75B | 38.14% | 28.93% | 25.01% | 22.95% |
| West Pharmaceutical Services, Inc. (WST)vs › | $26.23B | 18.89% | 16.95% | 19.08% | 20.56% |
| Biogen Inc. (BIIB)vs › | $33.88B | 4.43% | 8.42% | 11.86% | 16.52% |
ROE
14.5%
ROA
4.3%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 14.51% |
| 2026-03-31 | 14.11% |
| 2025-12-31 | 16.19% |
| 2025-09-30 | 22.18% |
| 2025-06-30 | 23.07% |
| 2025-03-31 | 23.76% |
| 2024-12-31 | 23.59% |
| 2024-09-30 | 20.15% |
| 2024-06-30 | 20.25% |
| 2024-03-31 | 21.19% |
| 2023-12-31 | 21.98% |
| 2023-09-30 | 24.11% |
| 2023-06-30 | 25.80% |
| 2023-03-31 | 28.39% |
| 2022-12-31 | 20.48% |
